Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > ARCHIVE
ARCHIVE
- Korosho Approves 2 Class 1 OTC Anti-allergic Eye Drops
May 30, 2011
- Daiichi Sankyo Launches SPRIX Nasal Spray in US
May 30, 2011
- Sanofi-aventis Changes Corporate Name to Sanofi
May 30, 2011
- NanoCarrier's NC-4016 to Obtain Substance Patent in US
May 30, 2011
- Takeda to Acquire Nycomed for 9.6 Bil. Euros
May 30, 2011
- JMA Formally Requests Postponement of Medical, Nursing Fee Revisions
May 30, 2011
- Top-10 Domestic Drug Makers' Sales, Profits Down due to Patent Expirations
May 30, 2011
- “Strict Warning”Issued to MSD for 4 Violations of Fair Promotion Code
May 30, 2011
- MTPC: Sales Up 1.2%, Double-digit Growth in Profits
May 30, 2011
- Asahi Kasei Pharma Obtains Marketing Approval for Flivas in South Korea
May 30, 2011
- DSP: Sales Up 28.1% through Acquisition of Sunovion of US
May 30, 2011
- Eisai's Novel Anticancer Drug Halaven Approved in Switzerland
May 30, 2011
- Shionogi: Net Profits Down 48.2% due to Earthquake, US Restructuring
May 30, 2011
- Ajinomoto, Mochida to Codevelop Fixed Dose CCB + ARB Combination from PIII
May 30, 2011
- Taisho: Operating Profits Up 27% due to Decreases in SGA Expenses
May 30, 2011
- Sales Down 0.5% due to Slump of Existing Products: Ono
May 30, 2011
- Glaucoma Treatments Drive Business: Santen
May 30, 2011
- Daiichi Sankyo: Growth in Sales, Double-digit Rise in Profits
May 23, 2011
- Korosho Asks Kyokai-kenpo to Further Promote Use of Generics
May 23, 2011
- Astellas: Sales, Profits Down on Lower Overseas Sales of Prograf, Harnal
May 23, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…